Clinical Trials
CD46 as an Imaging and Therapeutic Target for Prostate Cancer
CD46 is a type I membrane protein that binds to C3b and C4b, offering protection against complement-dependent cytotoxicity.1 In essence, it is an inhibitor complement receptor that serves as a negative regulator of the complement system.2 Therefore, it is logical that it would be upregulated during tumorigenesis to help early cancer cells evade immune detection and complement-dependent killing.3 In evaluating metastatic castration-resistant prostate cancer patients, CD46 mRNA levels are actually even higher than prostate-specific membrane antigen (PSMA); this could potentially be an encouraging imaging and therapeutic target, given the prior successes of PSMA-targeting in both of these areas.4
Evan Y. Yu, MD
Evan Yu, a medical oncologist, treats prostate, bladder, and testicular cancer and is passionate about providing a personalized medical approach to a selection of novel therapies as well as understanding biological mechanisms of drug sensitivity and resistance.
Clinical Expertise
Medical Oncology, Translational Research, Novel molecular targeted agents, Biomarkers, Imaging (PET scans, MRI), Bone health.
- Section Head, Cancer Medicine, Clinical Research Division Fred Hutchinson Cancer Center
- Medical Director, Clinical Research Support Fred Hutchinson Cancer Research Consortium
- Professor of Medicine Division of Oncology, Department of Medicine University of Washington School of Medicine Seattle, WA
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date. Please remember: Talk to your health care providers first before making decisions about your health care. Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.